# Padmanee Sharma

Source: https://onco.cc/people/padmanee-sharma/  
OnCo record `padmanee-sharma` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Runs the platform that studies patients' tumours before and after immunotherapy to learn why checkpoint drugs work or fail.

## Summary

Padmanee Sharma is Professor of Genitourinary Medical Oncology and Immunology and Scientific Director of the Immunotherapy Platform at MD Anderson Cancer Center. A medical oncologist and immunologist, she pioneered pre-surgical immunotherapy trials that study drug mechanisms in human tissue, examining patients' tumours before and after treatment to learn why checkpoint drugs work or fail. She co-leads the Parker Institute site at MD Anderson and the immunotherapy platform with James Allison, with work on ICOS, VISTA and resistance to checkpoint blockade. Her papers include a Cell review of primary, adaptive and acquired resistance to cancer immunotherapy and a Science perspective on the future of immune checkpoint therapy, spanning CTLA-4 and PD-1 in prostate, bladder and kidney cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Genitourinary Medical Oncology and Immunology; Scientific Director, Immunotherapy Platform, MD Anderson
- Specialisms: Immunotherapy; Genitourinary oncology; Translational immunology

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Padmanee_Sharma
- MD Anderson faculty: https://faculty.mdanderson.org/search?q=Padmanee%20Sharma
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Padmanee%20Sharma

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [PD-1](https://onco.cc/targets/pd1/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/), [Parker Institute for Cancer Immunotherapy](https://onco.cc/institutions/parker-institute/)
- key papers: [Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma](https://onco.cc/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/), [Leach, Krummel and Allison: releasing the CTLA-4 brake makes mice reject tumours](https://onco.cc/key-papers/paper-leach-allison-ctla4-blockade-science-1996/)

---
JSON: https://onco.cc/api/v1/entities/padmanee-sharma.json